Header Logo

Connection

STEVEN I SHERMAN to Carcinoma, Papillary

Back to Details
This is a "connection" page, showing publications STEVEN I SHERMAN has written about Carcinoma, Papillary.
STEVEN I SHERMAN
Connection Strength
3.596
Carcinoma, Papillary
  1. Reassessing the NTCTCS Staging Systems for Differentiated Thyroid Cancer, Including Age at Diagnosis. Thyroid. 2015 Oct; 25(10):1097-105.
    View in: PubMed
    Score: 0.391
  2. Long-Term Outcomes Following Therapy in Differentiated Thyroid Carcinoma: NTCTCS Registry Analysis 1987-2012. J Clin Endocrinol Metab. 2015 Sep; 100(9):3270-9.
    View in: PubMed
    Score: 0.388
  3. Clinical responses to vemurafenib in patients with metastatic papillary thyroid cancer harboring BRAF(V600E) mutation. Thyroid. 2013 Oct; 23(10):1277-83.
    View in: PubMed
    Score: 0.338
  4. Should papillary thyroid carcinoma be observed?: a word of caution. Arch Otolaryngol Head Neck Surg. 2010 May; 136(5):444-6.
    View in: PubMed
    Score: 0.270
  5. Recurrence after treatment of micropapillary thyroid cancer. Thyroid. 2009 Oct; 19(10):1043-8.
    View in: PubMed
    Score: 0.260
  6. Approach and safety of comprehensive central compartment dissection in patients with recurrent papillary thyroid carcinoma. Head Neck. 2009 Sep; 31(9):1152-63.
    View in: PubMed
    Score: 0.258
  7. Motesanib diphosphate in progressive differentiated thyroid cancer. N Engl J Med. 2008 Jul 03; 359(1):31-42.
    View in: PubMed
    Score: 0.238
  8. Outcomes of patients with differentiated thyroid carcinoma following initial therapy. Thyroid. 2006 Dec; 16(12):1229-42.
    View in: PubMed
    Score: 0.213
  9. How should you choose a thyroid surgeon? Thyroid. 2000 May; 10(5):439-41.
    View in: PubMed
    Score: 0.135
  10. The management of metastatic differentiated thyroid carcinoma. Rev Endocr Metab Disord. 2000 Apr; 1(3):165-71.
    View in: PubMed
    Score: 0.134
  11. American Thyroid Association Guidelines on the Management of Thyroid Nodules and Differentiated Thyroid Cancer Task Force Review and Recommendation on the Proposed Renaming of Encapsulated Follicular Variant Papillary Thyroid Carcinoma Without Invasion to Noninvasive Follicular Thyroid Neoplasm with Papillary-Like Nuclear Features. Thyroid. 2017 04; 27(4):481-483.
    View in: PubMed
    Score: 0.108
  12. Vemurafenib in patients with BRAF(V600E)-positive metastatic or unresectable papillary thyroid cancer refractory to radioactive iodine: a non-randomised, multicentre, open-label, phase 2 trial. Lancet Oncol. 2016 Sep; 17(9):1272-82.
    View in: PubMed
    Score: 0.104
  13. Follicular cell-derived thyroid cancer. Nat Rev Dis Primers. 2015 12 10; 1:15077.
    View in: PubMed
    Score: 0.100
  14. BRAF inhibitor dabrafenib in patients with metastatic BRAF-mutant thyroid cancer. Thyroid. 2015 Jan; 25(1):71-7.
    View in: PubMed
    Score: 0.093
  15. Long-term outcome of comprehensive central compartment dissection in patients with recurrent/persistent papillary thyroid carcinoma. Thyroid. 2011 Dec; 21(12):1309-16.
    View in: PubMed
    Score: 0.075
  16. Preoperative lateral neck ultrasonography as a long-term outcome predictor in papillary thyroid cancer. Arch Otolaryngol Head Neck Surg. 2011 Feb; 137(2):157-62.
    View in: PubMed
    Score: 0.071
  17. Clinical trials for progressive differentiated thyroid cancer: patient selection, study design, and recent advances. Thyroid. 2009 Dec; 19(12):1393-400.
    View in: PubMed
    Score: 0.066
  18. Revised American Thyroid Association management guidelines for patients with thyroid nodules and differentiated thyroid cancer. Thyroid. 2009 Nov; 19(11):1167-214.
    View in: PubMed
    Score: 0.065
  19. Postoperative external beam radiotherapy for differentiated thyroid cancer: outcomes and morbidity with conformal treatment. Int J Radiat Oncol Biol Phys. 2009 Jul 15; 74(4):1083-91.
    View in: PubMed
    Score: 0.062
  20. Nasolacrimal duct obstruction associated with radioactive iodine therapy for thyroid carcinoma. Ophthalmic Plast Reconstr Surg. 2003 Nov; 19(6):479-81.
    View in: PubMed
    Score: 0.043
  21. Outcome after treatment of high-risk papillary and non-H?rthle-cell follicular thyroid carcinoma. Ann Intern Med. 1998 Oct 15; 129(8):622-7.
    View in: PubMed
    Score: 0.030
  22. Targeted Therapy in Advanced Thyroid Cancer to Resensitize Tumors to Radioactive Iodine. J Clin Endocrinol Metab. 2018 10 01; 103(10):3698-3705.
    View in: PubMed
    Score: 0.030
  23. Efficacy and tolerability of vemurafenib in patients with BRAF(V600E) -positive papillary thyroid cancer: M.D. Anderson Cancer Center off label experience. J Clin Endocrinol Metab. 2015 Jan; 100(1):E77-81.
    View in: PubMed
    Score: 0.023
  24. Efficacy and tolerability of different starting doses of sorafenib in patients with differentiated thyroid cancer. Oncologist. 2014 May; 19(5):477-82.
    View in: PubMed
    Score: 0.022
  25. Diagnosis and management of differentiated thyroid cancer using molecular biology. Laryngoscope. 2013 Apr; 123(4):1059-64.
    View in: PubMed
    Score: 0.020
  26. In papillary thyroid cancer, preoperative central neck ultrasound detects only macroscopic surgical disease, but negative findings predict excellent long-term regional control and survival. Thyroid. 2012 Apr; 22(4):347-55.
    View in: PubMed
    Score: 0.019
  27. The successful use of sorafenib to treat pediatric papillary thyroid carcinoma. Thyroid. 2009 Apr; 19(4):407-12.
    View in: PubMed
    Score: 0.016
  28. Epidermal growth factor receptor (EGFR) is overexpressed in anaplastic thyroid cancer, and the EGFR inhibitor gefitinib inhibits the growth of anaplastic thyroid cancer. Clin Cancer Res. 2004 Dec 15; 10(24):8594-602.
    View in: PubMed
    Score: 0.012
  29. Fine-needle aspiration of the thyroid and correlation with histopathology in a contemporary series of 240 patients. Am J Surg. 2003 Dec; 186(6):702-9; discussion 709-10.
    View in: PubMed
    Score: 0.011
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.